Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol

  • STATUS
    Recruiting
  • participants needed
    400
  • sponsor
    e-GLORIA trial Protocol Review Committee
Updated on 7 November 2020

Summary

The purpose of this study is to evaluate the efficacy and safety of eldecalcitol monotherapy compared with alfacalcidol monotherapy in patients with glucocorticoid-induced osteoporosis, using a randomized, open-label, parallel-group, comparative design.

Details
Condition Osteoporosis
Treatment Eldecalcitol, Alfacalcidol
Clinical Study IdentifierNCT01974167
Sponsore-GLORIA trial Protocol Review Committee
Last Modified on7 November 2020

Eligibility

Yes No Not Sure

Inclusion Criteria

(1) Patients who are currently taking or plan to take oral glucocorticoid medication for 3 months or longer and thus require treatment as per the 'Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and mineral Research (2004),' and who meet at least one of the conditions below. No restriction is imposed on the underlying disease treated with the oral glucocorticoid medication
(i) Have any existing insufficiency fracture (ii) %YAM <80 (iii) Oral
glucocorticoid daily dose >= 5 mg prednisolone equivalent
(2) Aged between 20 and 85 years (both inclusive) at consent
(3) Patients who are able to walk without assistance
(4) Provided consent to participate in the study

Exclusion Criteria

(1) BMD (L1-4 or T-Hip) T score < -3.5
(2) Have 3 or more vertebral fractures between L1 and L4
(3) Have 1 or more SQ grade 3 vertebral fractures, or 3 or more SQ grade 2 vertebral fractures
(4) Have received a bisphosphonate preparation for 2 weeks or longer within 6 months before the start of study treatment
(5) Have received a bisphosphonate preparation for 2 years or longer within 3 years before the start of study treatment
(6) Have received a parathyroid hormone preparation before the start of study treatment
(7) Have received one or more doses of an anti-RANKL (receptor activator of nuclear factor-kappa B ligand) antibody
(8) Have received one or more doses of an anti-sclerostin antibody or cathepsin K inhibitor
(9) Have received any other investigational product (including placebo) within 16 weeks before the start of study treatment in the present study
(10) Have received any of the following drugs that can affect bone metabolism within 8 weeks before the start of study treatment, with the exception of calcium preparations: (i) Bisphosphonates (ii) Active vitamin D preparations (including those for topical use) (iii) Selective estrogen receptor modulators (SERMs) (iv) Calcitonin preparations (v) Vitamin K2 preparations (vi) Ipriflavone preparations (vii) Reproductive hormone products (except those for vaginal use such as vaginal tablets and creams) (viii) Other drugs that can affect bone metabolism
(11) Pregnant woman or woman who desires to become pregnant
(12) Have corrected serum calcium >= 10.4 mg/dL or < 8.0 mg/dL at enrollment
(13) Have corrected urinary calcium > 0.4 mg/dL GF at enrollment
(14) Have a past or current history of urinary calculus
(15) Have eGFR < 30 mL/min/1.73 m2 at enrollment
(16) Have severe liver disease such as cirrhosis or severe heart disease such as severe cardiac failure
(17) Have active malignancy or received treatment for malignancy, including adjuvant therapy, within the past 3 years
(18) Have a history of hypersensitivity to eldecalcitol, alfacalcidol, or other vitamin D preparations
(19) Other persons judged by the investigator (or subinvestigator) to be inappropriate to participate in this study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note